Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-07-01 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
TOTAL VOTING RIGHTS
Foreign Filer Report
2022-07-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification filed via RNS (London Stock Exchange news service) concerning 'Voting rights and capital'. It explicitly states the total number of voting rights as of June 30, 2022, which is required under the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of regulatory disclosure regarding the total number of shares with voting rights is a specific regulatory announcement. While it relates to capital structure, it is not a financing event (CAP) or a share repurchase (POS). It is a mandatory regulatory disclosure that fits best under the general 'Regulatory Filings' category (RNS) as it is a standard, periodic disclosure mandated by the FCA, distinct from the other specific filing types listed. Given the source (RNS Number) and content (Voting Rights/Capital disclosure), RNS is the most appropriate classification.
2022-07-01 English
IMFINZI IMPROVED PCR IN RESECTABLE LUNG CANCER
Foreign Filer Report
2022-06-30 English
Imfinzi improved pCR in resectable lung cancer
Regulatory Filings Classification · 99% confidence The document is identified by the header 'RNS Number : 7287Q' and concludes with information provided by 'RNS, the news service of the London Stock Exchange.' This indicates it is a regulatory announcement disseminated through the RNS system. The content details positive clinical trial results (AEGEAN Phase III trial for Imfinzi) and provides extensive scientific and corporate background. Since this is a specific announcement of clinical data/corporate news that is being disseminated via the RNS system, and it is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI), the most appropriate classification is the general regulatory announcement fallback category, RNS. The document length (12,414 chars) is substantial, meaning it is the primary announcement itself, not just a notice of publication (RPA).
2022-06-30 English
ANNUAL REPORT
Regulatory Filings
2022-06-29 English
ENHERTU RECOMMENDED FOR BREAST CANCER EU APPROVAL
Foreign Filer Report
2022-06-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.